Mn Services Vermogensbeheer B.V. Lowers Position in DaVita Inc. (NYSE:DVA)

Mn Services Vermogensbeheer B.V. lessened its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 10.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,380 shares of the company's stock after selling 2,200 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in DaVita were worth $2,965,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of DVA. Epoch Investment Partners Inc. purchased a new position in shares of DaVita during the 4th quarter valued at $55,100,000. Invesco Ltd. lifted its position in shares of DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the last quarter. Iron Triangle Partners LP purchased a new position in shares of DaVita during the 4th quarter valued at $38,946,000. Amundi lifted its position in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock valued at $35,919,000 after buying an additional 233,222 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Finally, Truist Financial dropped their price target on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus target price of $164.50.

DaVita Price Performance

DVA traded up $0.87 during trading on Friday, reaching $136.66. 1,711,072 shares of the company were exchanged, compared to its average volume of 804,663. The company's 50-day moving average is $139.84 and its two-hundred day moving average is $150.10. The company has a market cap of $10.32 billion, a price-to-earnings ratio of 13.54, a P/E/G ratio of 0.94 and a beta of 1.11. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $131.76 and a 12-month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The business had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the prior year, the firm posted $2.26 EPS. The firm's quarterly revenue was up 5.0% on a year-over-year basis. Research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.